DexCom price target lowered to $99 from $115 at Raymond James

Raymond James lowered the firm’s price target on DexCom (DXCM) to $99 from $115 and keeps a Strong Buy rating on the shares. DexCom’s Q3 results provided modest upside to consensus, but Raymond James predicts the debate around U.S. pricing and mix will continue, but is encouraged with the demand profile and sees a path to accelerating revenue growth over the next few quarters, the analyst tells investors in a research note.